Clinical trial
A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment
NCT01116193 is registered in ClinicalTrials.gov with Institut de Cancérologie de la Loire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment
- Lead sponsor
- Institut de Cancérologie de la Loire
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2010
- Completion date
- August 31, 2013
- Enrollment
- 10 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.